Читать книгу Genomic and Epigenomic Biomarkers of Toxicology and Disease - Группа авторов - Страница 21

1 Califf, R.M. (2018). Biomarker definitions and their applications. Exp. Biol. Med. (Maywood) 243 (3): 213–221. Published online 2018 Feb 6. https://doi.org/10.1177/1535370217750088.

2 Chorley, B.N., Ellinger-Ziegelbauer, H., Tackett, M., Simutis, F.J., Harrill, A.H., McDuffie, J., Atabakhsh, E., Nassirpour, R., Whiteley, L.O., Léonard, J., Carswell, G.K., Harpur, E., Chen, C.L., and Gautier, J. (2021). Urinary miRNA biomarkers of drug-induced kidney injury and their site specificity within the nephron. Toxicol. Sci. 180 (1): 1–16. https://doi.org/10.1093/toxsci/kfaa181.

3 de Gannes, M., Ko, C., Zhang, X., Biesiada, J., Niu, L., Koch, S.E., Medvedovic, M., Rubinstein, J., and Puga, A. (2020). Dioxin disrupts dynamic DNA methylation patterns in genes that govern cardiomyocyte maturation. Toxicol. Sci. 178 (2): 325–337. https://doi.org/10.1093/toxsci/kfaa153.

4 Dolinoy, D.C. and Jirtle, R.L. (2008). Environmantal epigenomics in human health and disease. Environ. Mol. Mutagen. 49 (1): 4–8.

5 Friedman, R.C., Farh, K.K., Burge, C.B., and Bartel, D.P. (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genom. Res. 19: 92–105.

6 Jeyaraman, S., Hanif, E.A.M., Ab Mutalib, N.S., Jamal, R., and Abu, N. (2019). Circular RNAs: Potential regulators of treatment resistance in human cancers. Front. Genet. 10: 1369.

7 Jones, P.A. (2012). Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13: 484–492.

8 Judson, R., Houck, K., Martin, M., Richard, A.M., Knudsen, T.B., Shah, I., Little, S., Wambaugh, J., Setzer, R.W., Kothya, P., Phuong, J., File, D., Smith, D., Reif, D., Rotroff, D., Kleinstreuer, N., Sipes, N., Xia, M., Huang∣, R., Crofton, K., and Thomas, R.S. (2016). Analysis of the effects of cell stress and cytotoxicity on in vitro assay activity across a diverse chemical and assay space. Toxicol. Sci. 152 (2): 323–339.

9 Judson, R., Kavlock, R., Martin, M., Reif, D., Houck, K., Knudsen, T., Richard, A., Tice, R.R., Whelan, M., Xia, M., Huang, R., Austin, C., Daston, G., Hartung, T., Fowle, J.R., Wooge, W., Tong, W., and Dix, D. (2013). Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. ALTEX 30 (1): 51–56.

10 Krewski, D., Acosta, D., Andersen, M., Anderson, H., Bailar, J.C., Boekelheide, K., Brent, R., Charnley, G., Cheung, V.G., Green, S., Kelsey, K.T., Kerkvliet, N.I., Li, A.A., McCray, L., Meyer, O., Patterson, R.D., Pennie, W., Scala, R.A., Solomon, G.M., Stephens, M., Yager, J., and Zeise, L. (2010). Toxicity testing in the 21st century: A vision and a strategy. J. Toxicol. Environ. Health. B. Crit. Rev. 2010 Feb 13 (0): 51–138. 10.1080/10937404.2010.483176.

11 Lee, R.C., Feinbaum, R.L., and Ambros, V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843–854.

12 Li, C.Y. and Cui, J.Y. (2018). Regulation of protein-coding gene and long noncoding RNA pairs in liver of conventional and germ-free mice following oral PBDE exposure. Plos One 13: e0201387.

13 Li, D., Knox, B., Gong, B., Chen, S., Guo, L., Liu, Z., Tong, W., and Ning, B. (2021). Identification of translational microRNA biomarker candidates for ketoconazole-induced liver injury using next-generation sequencing. Toxicol. Sci. 179 (1): 31–43. https://doi.org/10.1093/toxsci/kfaa162.

14 Lin, C., Yuan, G., Hu, Z., Zeng, Y., Qiu, X., Yu, H., and He, S. (2019). Bioinformatics analysis of the interactions among lncRNA, miRNA and mRNA expression, genetic mutations and epigenetic modifications in hepatocellular carcinoma. Mol. Med. Rep. 19: 1356–1364. https://doi.org/10.3892/mmr.2018.9728.

15 Livingstone, M.C., Johnson, N.M., Roebuck, B.D., Kensler, T.W., and Groopman, J.D. (2019). Serum miR-182 is a predictive biomarker for dichotomization of risk of hepatocellular carcinoma in rats. Mol. Carcinog. 58: 2017–2025. https://doi.org/10.1002/mc.23093.

16 NAS (U.S. National Academy of Sciences). (2007). Toxicity Testing in the 21st Century: A Vision and A Strategy. Washington, DC: National Academy Press.

17 Otsuka, M., Kishikawa, T., Yoshikawa, T., Yamagami, M., Ohno, M., Takata, A., Shibata, C., Ishibashi, R., and Koike, K. (2017). MicroRNAs and liver disease. J. Hum. Genet. 62: 75–80. https://doi.org/10.1038/jhg.2016.53.

18 Robb, M.A., McInnes, P.M., and Califf, R.M. (2016). Biomarkers and surrogate endpoints: Developing common terminology and definitions. JAMA 2016 315: 1107–1108.

19 Schueller, F., Roy, S., Vucur, M., Trautwein, C., Lurdde, T., and Roderberg, C. (2018). The role of miRNA in the pathophyisiology of liver diseases and toxicity. Int. J. Mol. Sci. 19: 261–269.

20 Shao, Y. and Jiang, Y. (2021). Circular RNAs in Toxicology. Toxicol. Sci. 179 (2): 149–161. https://doi.org/10.1093/toxsci/kfaa173.

21 Woodcock, J. (2009). Chutes and ladders on the critical path: Comparative effectiveness, product value, and the use of biomarkers in drug development. Clin. Pharmacol. Ther. 86 (1): 12–14.